High-Value-Added Products and Overseas Expansion through a Capital and Business Alliance with Rohto Pharmaceutical
First written in FY2021. 4 of 5 entries say "Advanced", first in FY2022-Q1. Latest entry: FY2022.
No other company in this theme has enough history to compare yet.
- FY2022AdvancedAnnual report
「The company also conducted cross-selling of ROHTO PHARMACEUTICAL CO.,LTD.’s eye-care supplement, “Rohto V5 Tsubu Act Vision,” to customers who purchased the eyeglass-style magnifier “PFI Hakase LoupeⓇ.” Sales generated by combining the strengths of both companies amounted to ¥1,149 million, compared with ¥8 million in the previous fiscal year.」
Cross-selling sales under the alliance with ROHTO PHARMACEUTICAL CO.,LTD. increased to ¥1,149 million. - FY2022-Q3AdvancedAnnual report
「The company also conducted cross-selling of ROHTO PHARMACEUTICAL CO.,LTD.’s eye-care supplement, “Rohto V5 Tsubu Act Vision,” to customers who purchased the eyeglass-style magnifier “PFI Hakase LoupeⓇ.” Sales generated by combining the strengths of both companies amounted to ¥864 million.」
The company continued cross-selling under its alliance with ROHTO PHARMACEUTICAL CO.,LTD., and sales increased from ¥476 million previously to ¥864 million. - FY2022-Q2AdvancedAnnual report
「The company also conducted cross-selling of ROHTO PHARMACEUTICAL CO.,LTD.’s eye-care supplement, “Rohto V5 Tsubu Act Vision,” to customers who purchased the eyeglass-style magnifier “PFI Hakase LoupeⓇ.” Sales generated by combining the strengths of both companies amounted to ¥476 million.」
Under the alliance with ROHTO PHARMACEUTICAL CO.,LTD., the company conducted cross-selling of the eye-care supplement and recorded sales of ¥476 million. - FY2022-Q1AdvancedAnnual report
「The company also conducted cross-selling of ROHTO PHARMACEUTICAL CO.,LTD.’s eye-care supplement, “Rohto V5 Tsubu Act Vision,” to customers who purchased the eyeglass-style magnifier “PFI Hakase LoupeⓇ.” Sales generated by combining the strengths of both companies amounted to ¥194 million.」
Under the alliance with ROHTO PHARMACEUTICAL CO.,LTD., the company conducted cross-selling of the partner’s products and recorded sales of ¥194 million. - FY2021First statedAnnual report
「ⅰ. Development of high-value-added products ⅱ. Expansion of sales of developed products (a) Expansion of sales in China and Southeast Asia (b) Expansion of sales in the direct-to-consumer business ⅲ. Establishment of overseas production systems for functional materials and developed products」
On 16 July 2021, the company entered into a capital and business alliance agreement with ROHTO PHARMACEUTICAL CO.,LTD. The companies will discuss the development of high-value-added products, expansion of sales in China, Southeast Asia and the direct-to-consumer channel, and the establishment of overseas production systems. The framework also includes reciprocal share acquisitions.